INT179687

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 5.37
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
bone marrow 4
liver 2
lungs 2
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 17 99.20 Very High Very High Very High
Inflammation 100 85.48 High High
Inflammatory mediators 4 73.16 Quite High
cytokine 18 56.36 Quite High
metalloproteinase 22 50.00 Quite Low
COX2 1 50.00 Quite Low
ischemia 6 47.92 Quite Low
anesthesia 3 18.20 Low Low
dexamethasone 10 5.00 Very Low Very Low Very Low
corticosteroid 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperoxia 15 99.86 Very High Very High Very High
Emphysema 54 99.48 Very High Very High Very High
Death 20 99.28 Very High Very High Very High
Leukemia 50 98.42 Very High Very High Very High
Apoptosis 17 97.04 Very High Very High Very High
Cancer 166 96.48 Very High Very High Very High
Solid Tumor 29 92.28 High High
Hypoxia 53 87.12 High High
INFLAMMATION 115 85.48 High High
Disease 67 81.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
“Angiogenesis switch” in leukemia is documented by increased bone marrow MVD (Figures 2(a) and 2(b)), increased expression of HIF-1, multiple proangiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [11, 12].
Negative_regulation (decreased) of Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
1) Confidence 0.22 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.05 Pain Relevance 0
“Angiogenesis switch” in leukemia is documented by increased bone marrow MVD (Figures 2(a) and 2(b)), increased expression of HIF-1, multiple proangiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [11, 12].
Negative_regulation (decreased) of Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
2) Confidence 0.22 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.03 Pain Relevance 0
inhibit endothelial VEGFR-2 expression by repressing transactivation and
Negative_regulation (inhibit) of Gene_expression (expression) of VEGFR-2
3) Confidence 0.13 Published 2008 Journal PPAR Research Section Body Doc Link PMC2490577 Disease Relevance 0.83 Pain Relevance 0.19
In preclinical models, sunitinib administration resulted in significant reduction in phos-photyrosine levels of VEGFR-2, PDGFR-?
Negative_regulation (reduction) of Gene_expression (levels) of VEGFR
4) Confidence 0.11 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.72 Pain Relevance 0
However, in a different study arm using the same model, we found that hyperoxia alone decreased the expression of VEGFR2 and TGFBR3 in liver tissue compared with the otherwise equally treated control group.
Negative_regulation (decreased) of Gene_expression (expression) of VEGFR2 in liver associated with hyperoxia
5) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3000320 Disease Relevance 0.53 Pain Relevance 0
An increased septal cell death in human emphysematous lungs and a reduced expression of VEGF and VEGFR-2 is found in emphysema lungs [181].
Negative_regulation (reduced) of Gene_expression (expression) of VEGFR-2 in lungs associated with emphysema and death
6) Confidence 0.02 Published 2004 Journal Respir Res Section Body Doc Link PMC533858 Disease Relevance 1.20 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox